| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454117 | Lung Cancer | 2018 | 7 Pages |
Abstract
Our study identified Topo-II expression as a significant biomarker for the prediction of favorable outcomes in patients with relapsed SCLCs who underwent treatment with amrubicin, a Topo-II inhibitor. Thus, Topo-II expression may be a promising predictor of the efficacy of amrubicin.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Yosuke Miura, Kyoichi Kaira, Reiko Sakurai, Noriaki Sunaga, Ryusei Saito, Takeshi Hisada, Masanobu Yamada,